Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of ALVR105 (Viralym-M) Compared to Placebo for the Prevention of AdV, BKV, CMV, EBV, HHV-6, and JCV Infection and/or Disease, in High-Risk Patients After Allogeneic Hematopoietic Cell Transplant

Primary Objective

To compare the efficacy of ALVR105 to placebo in the proportion of patients with clinically significant AdV, BKV, CMV, EBV, HHV-6, and/or JCV infection and/or end-organ disease as determined by an independent, blinded Clinical Adjudication Committee (CAC) through Week 14

Is this Study for You?

Let's Get Started!

Details
Age

Adult

Type of Study

Prevention

Locations

University of Colorado Hospital

Principal Investigator
Photograph of Jonathan Gutman,  MD

Jonathan Gutman, MD

Study ID

Protocol Number: 20-2670

More information available at ClinicalTrials.gov: NCT04693637

Categories

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers